Epigenetic therapy for solid tumors: From bench science to clinical trials

Epigenomics

Volumn 7, Issue 2, 2015, Pages 215-235

  Juo, Yen Yi ^a   Gong, Xue Jun ^b,c   Mishra, Ankita ^b   Cui, Xiao ^b   Baylin, Stephen B ^b   Azad, Nilofer S ^b   Ahuja, Nita ^b  

^a GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

cancer therapy; clinical trials; DNA methyltransferase inhibitor; epigenetics; histone deacetylase inhibitor; solid tumor

Indexed keywords

DNA METHYLTRANSFERASE INHIBITOR; HISTONE DEACETYLASE INHIBITOR; ANTINEOPLASTIC AGENT;

CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER PATIENT; CHROMATIN; CLINICAL TRIAL (TOPIC); CPG ISLAND; DNA METHYLATION; EPIGENETICS; GENE SILENCING; HEMATOLOGIC MALIGNANCY; HISTONE MODIFICATION; HUMAN; MONOTHERAPY; PATIENT SELECTION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; REVIEW; SOLID TUMOR; TREATMENT OUTCOME; TUMOR SUPPRESSOR GENE; DRUG EFFECTS; GENETIC EPIGENESIS; GENETICS; NEOPLASMS;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS AS TOPIC; DNA METHYLATION; EPIGENESIS, GENETIC; HISTONE DEACETYLASE INHIBITORS; HUMANS; NEOPLASMS;

EID: 84928889477     PISSN: 17501911     EISSN: 1750192X     Source Type: Journal    
DOI: 10.2217/epi.14.73     Document Type: Review

References (169)

1. Holliday R. DNA methylation and epigenotypes. Biochemistry (Mosc.) 70(5), 500-504 (2005).
2. Rothbart SB, Strahl BD. Interpreting the language of histone and DNA modifications. Biochim. Biophys. Acta 1839(8), 627-643 (2014).
3. Kouzarides T. Histone methylation in transcriptional control. Curr. Opin. Genet. Dev. 12(2), 198-209 (2002).
4. Friedman RC, Farh KK, Burge CB, Bartel DP. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res. 19(1), 92-105 (2009).
5. Azad N, Zahnow CA, Rudin CM, Baylin SB. The future of epigenetic therapy in solid tumours - lessons from the past. Nat. Rev. Clin. Oncol. 10(5), 256-266 (2013).
6. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N. Engl. J. Med. 349(21), 2042-2054 (2003).
7. Feinberg AP, Vogelstein B. Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature 301(5895), 89-92 (1983).
8. Seligson DB, Horvath S, Shi T et al. Global histone modification patterns predict risk of prostate cancer recurrence. Nature 435(7046), 1262-1266 (2005).
9. Feinberg AP, Ohlsson R, Henikoff S. The epigenetic progenitor origin of human cancer. Nat. Rev. Genet. 7(1), 21-33 (2006).
10. Suzuki H, Maruyama R, Yamamoto E, Kai M. Epigenetic alteration and microRNA dysregulation in cancer. Front. Genet. 4, 258 (2013).
11. Rhee I, Bachman KE, Park BH et al. DNMT1 and DNMT3b cooperate to silence genes in human cancer cells. Nature 416(6880), 552-556 (2002).
12. Esteller M. Cancer epigenomics: DNA methylomes and histone-modification maps. Nat. Rev. Genet. 8(4), 286-298 (2007).
13. Holliday R, Jeggo PA. Mechanisms for changing gene expression and their possible relationship to carcinogenesis. Cancer Surv. 4(3), 557-581 (1985).
14. Jones PA, Taylor SM. Cellular differentiation, cytidine analogs and DNA methylation. Cell 20(1), 85-93 (1980).
15. Ahuja N, Easwaran H, Baylin SB. Harnessing the potential of epigenetic therapy to target solid tumors. J. Clin. Invest. 124(1), 56-63 (2014).
16. Egger G, Liang G, Aparicio A, Jones PA. Epigenetics in human disease and prospects for epigenetic therapy. Nature 429(6990), 457-463 (2004).
17. Van Kampen JG, Marijnissen-Van Zanten MA, Simmer F, Van Der Graaf WT, Ligtenberg MJ, Nagtegaal ID. Epigenetic targeting in pancreatic cancer. Cancer. Treat. Rev. 40(5), 656-664 (2013).
18. Jakopovic M, Thomas A, Balasubramaniam S, Schrump D, Giaccone G, Bates SE. Targeting the epigenome in lung cancer: expanding approaches to epigenetic therapy. Front. Oncol. 3, 361 (2013).
19. Ushijima T, Takeshima H. Epigenetics as a novel therapeutic target of cancer. Gan To Kagaku Ryoho 40(11), 1429-1435 (2013).
20. Geutjes EJ, Bajpe PK, Bernards R. Targeting the epigenome for treatment of cancer. Oncogene 31(34), 3827-3844 (2012)
21. ClinicalTrials.gov. NCT01696032 (2012).
22. Tsai HC, Li H, Van Neste L et al. Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells. Cancer Cell 21(3), 430-446 (2011).
23. Juergens RA, Wrangle J, Vendetti FP et al. Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer. Cancer Discov. 1(7), 598-607 (2011).
24. Li H, Chiappinelli KB, Guzzetta AA et al. Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers. Oncotarget 5(3), 587-598 (2014).
25. Borodovsky A, Salmasi V, Turcan S et al. 5-azacytidine reduces methylation, promotes differentiation and induces tumor regression in a patient-derived IDH1 mutant glioma xenograft. Oncotarget 4(10), 1737-1747 (2013).
26. Turcan S, Fabius AW, Borodovsky A et al. Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT inhibitor decitabine. Oncotarget 4(10), 1729-1736 (2013).
27. Lu HP, Chao CC. Cancer cells acquire resistance to anticancer drugs: an update. Biomed. J. 35(6), 464-472 (2012).
28. Crea F, Nobili S, Paolicchi E et al. Epigenetics and chemoresistance in colorectal cancer: an opportunity for treatment tailoring and novel therapeutic strategies. Drug Resist. Updat. 14(6), 280-296 (2011).
29. Vatapalli RJ, Guzetta AA, Fu T, Syed L, Kwak R, Ahuja N. Improving sensitivity to Irinotecan using 5-Azacytidine in colon cancer cell lines. Association for Academic Surgery & Society of University Surgeons 179(2), 251-252 (2014).
30. Cacan E, Ali MW, Boyd NH, Hooks SB, Greer SF. Inhibition of HDAC1 and DNMT1 modulate RGS10 expression and decrease ovarian cancer chemoresistance. PLoS ONE 9(1), e87455 (2014).
31. Hehlgans S, Storch K, Lange I, Cordes N. The novel HDAC inhibitor NDACI054 sensitizes human cancer cells to radiotherapy. Radiother. Oncol. 109(1), 126-132 (2013).
32. Karaca B, Atmaca H, Bozkurt E et al. Combination of AT-101/ cisplatin overcomes chemoresistance by inducing apoptosis and modulating epigenetics in human ovarian cancer cells. Mol. Biol. Rep. 40(6), 3925-3933 (2012).
33. Hubaux R, Vandermeers F, Crisanti MC et al. Preclinical evidence for a beneficial impact of valproate on the response of small cell lung cancer to first-line chemotherapy. Eur. J. Cancer 46(9), 1724-1734 (2010).
34. Issa JP. Optimizing therapy with methylation inhibitors in myelodysplastic syndromes: dose, duration, and patient selection. Nat. Clin. Pract. Oncol. 2(Suppl. 1), S24-S29 (2005).
35. Kaminskas E, Farrell AT, Wang YC, Sridhara R, Pazdur R. FDA drug approval summary: azacitidine (5-azacytidine, Vidaza) for injectable suspension. Oncologist 10(3), 176-182 (2005).
36. Silverman LR. DNA methyltransferase inhibitors in myelodysplastic syndrome. Best Pract. Res. Clin. Haematol. 17(4), 585-594 (2004).
37. Whittaker SJ, Demierre MF, Kim EJ et al. Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. J. Clin. Oncol. 28(29), 4485-4491 (2010).
38. Sorm F, Vesely J. The activity of a new antimetabolite, 5-Azacitidine, against lymphoid leukaemia in Ak mice. Neoplasma 11, 123-130 (1964).
39. Stresemann C, Lyko F. Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine. Int. J. Cancer 123(1), 8-13 (2008).
40. Qin T, Youssef EM, Jelinek J et al. Effect of cytarabine and decitabine in combination in human leukemic cell lines. Clin. Cancer Res. 13(14), 4225-4232 (2007).
41. Abele R, Clavel M, Dodion P et al. The EORTC Early Clinical Trials cooperative group experience with 5-aza-2- deoxycytidine (NSC 127716) in patients with colo-rectal, head and neck, renal carcinomas and malignant melanomas. Eur. J. Cancer Clin. Oncol. 23(12), 1921-1924 (1987).
42. Cowan LA, Talwar S, Yang AS. Will DNA methylation inhibitors work in solid tumors? A review of the clinical experience with azacitidine and decitabine in solid tumors. Epigenomics 2(1), 71-86 (2010).
43. Clavel M, Monfardini S, Fossa S, Smyth J, Renard J, Kaye SB. 5-Aza-2-deoxycytidine (NSC 127716) in nonseminomatous testicular cancer. Phase II from the EORTC Early Clinical Trials Cooperative Group and Genito-Urinary Group. Ann. Oncol. 3(5), 399-400 (1992).
44. Stadler WM, Margolin K, Ferber S, Mcculloch W, Thompson JA. A Phase II study of depsipeptide in refractory metastatic renal cell cancer. Clin. Genitourin. Cancer 5(1), 57-60 (2006).
45. Kornblith AB, Herndon JE, 2nd, Silverman LR et al. Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized Phase III trial: a cancer and leukemia group B study. J. Clin. Oncol. 20(10), 2441-2452 (2002).
46. Silverman LR, Demakos EP, Peterson BL et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J. Clin. Oncol. 20(10), 2429-2440 (2002).
47. Broske Am, Vockentanz L, Kharazi S et al. DNA methylation protects hematopoietic stem cell multipotency from myeloerythroid restriction. Nat. Genet. 41(11), 1207-1215 (2009).
48. Lizardi PM. As we bring demethylating drugs to the clinic, we better know the DICE being cast. Oncogene 29(43), 5772-5774 (2010).
49. Eden A, Gaudet F, Waghmare A, Jaenisch R. Chromosomal instability and tumors promoted by DNA hypomethylation. Science 300(5618), 455 (2003).
50. Yan L, Nass SJ, Smith D, Nelson WG, Herman JG, Davidson NE. Specific inhibition of DNMT1 by antisense oligonucleotides induces re-expression of estrogen receptoralpha (ER) in ER-negative human breast cancer cell lines. Cancer Biol. Ther. 2(5), 552-556 (2003).
51. Yoo CB, Jeong S, Egger G et al. Delivery of 5-aza-2- deoxycytidine to cells using oligodeoxynucleotides. Cancer Res. 67(13), 6400-6408 (2007).
52. Chuang JC, Warner Sl, Vollmer D et al. S110, a 5-Aza-2- deoxycytidine-containing dinucleotide, is an effective DNA methylation inhibitor in vivo and can reduce tumor growth. Mol. Cancer Ther. 9(5), 1443-1450 (2010).
53. Coral S, Parisi G, Nicolay HJ et al. Immunomodulatory activity of SGI-110, a 5-aza-2-deoxycytidine-containing demethylating dinucleotide. Cancer Immunol. Immunother. 62(3), 605-614 (2013).
54. Tellez CS, Grimes MJ, Picchi MA et al. SGI-110 and entinostat therapy reduces lung tumor burden and reprograms the epigenome. Int. J. Cancer 135(9), 2223-2231 (2014).
55. ClinicalTrials.gov. NCT01752933 (2012).
56. ClinicalTrials.gov. NCT01896856 (2013).
57. Song Y, Zhang C. Hydralazine inhibits human cervical cancer cell growth in vitro in association with APC demethylation and re-expression. Cancer Chemother. Pharmacol. 63(4), 605-613 (2009).
58. Candelaria M, Gallardo-Rincon D, Arce C et al. A Phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors. Ann. Oncol. 18(9), 1529-1538 (2007).
59. De La Cruz-Hernandez E, Perez-Plasencia C, Perez-Cardenas E et al. Transcriptional changes induced by epigenetic therapy with hydralazine and magnesium valproate in cervical carcinoma. Oncol. Rep. 25(2), 399-407 (2010).
60. Coronel J, Cetina L, Pacheco I et al. A double-blind, placebocontrolled, randomized Phase III trial of chemotherapy plus epigenetic therapy with hydralazine valproate for advanced cervical cancer. Preliminary results. Med. Oncol. 28(Suppl. 1), S540-S546 (2010).
61. Momparler Rl, Bouffard DY, Momparler LF, Dionne J, Belanger K, Ayoub J. Pilot Phase I-II study on 5-aza-2- deoxycytidine (Decitabine) in patients with metastatic lung cancer. Anticancer Drugs 8(4), 358-368 (1997).
62. Thibault A, Figg Wd, Bergan RC et al. A Phase II study of 5-aza-2deoxycytidine (decitabine) in hormone independent metastatic (D2) prostate cancer. Tumori 84(1), 87-89 (1998).
63. Schwartsmann G, Schunemann H, Gorini CN et al. A Phase I trial of cisplatin plus decitabine, a new DNAhypomethylating agent, in patients with advanced solid tumors and a follow-up early Phase II evaluation in patients with inoperable non-small cell lung cancer. Invest. New Drugs 18(1), 83-91 (2000).
64. Pohlmann P, Dileone LP, Cancella AI et al. Phase II trial of cisplatin plus decitabine, a new DNA hypomethylating agent, in patients with advanced squamous cell carcinoma of the cervix. Am. J. Clin. Oncol. 25(5), 496-501 (2002).
65. Turner BM. Cellular memory and the histone code. Cell 111(3), 285-291 (2002).
66. De Ruijter AJ, Van Gennip AH, Caron HN, Kemp S, Van Kuilenburg AB. Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem. J. 370(Pt 3), 737-749 (2003).
67. Vidanes GM, Bonilla CY, Toczyski DP. Complicated tails: histone modifications and the DNA damage response. Cell 121(7), 973-976 (2005).
68. Weinreich M, Palacios Debeer MA, Fox CA. The activities of eukaryotic replication origins in chromatin. Biochim. Biophys. Acta 1677(1-3), 142-157 (2004).
69. Bode AM, Dong Z. Post-translational modification of p53 in tumorigenesis. Nat. Rev. Cancer 4(10), 793-805 (2004).
70. Boyes J, Byfield P, Nakatani Y, Ogryzko V. Regulation of activity of the transcription factor GATA-1 by acetylation. Nature 396(6711), 594-598 (1998).
71. Martinez-Balbas MA, Bauer Um, Nielsen SJ, Brehm A, Kouzarides T. Regulation of E2F1 activity by acetylation. EMBO J 19(4), 662-671 (2000).
72. Chan HM, Krstic-Demonacos M, Smith L, Demonacos C, La Thangue NB. Acetylation control of the retinoblastoma tumour-suppressor protein. Nat. Cell. Biol. 3(7), 667-674 (2001).
73. Jeong JW, Bae MK, Ahn MY et al. Regulation and destabilization of HIF-1alpha by ARD1-mediated acetylation. Cell 111(5), 709-720 (2002).
74. Minucci S, Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat. Rev. Cancer 6(1), 38-51 (2006).
75. Munster PN, Troso-Sandoval T, Rosen N, Rifkind R, Marks PA, Richon VM. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells. Cancer Res. 61(23), 8492-8497 (2001).
76. Said TK, Moraes RC, Sinha R, Medina D. Mechanisms of suberoylanilide hydroxamic acid inhibition of mammary cell growth. Breast Cancer Res. 3(2), 122-133 (2001).
77. Huang L, Sowa Y, Sakai T, Pardee AB. Activation of the p21WAF1/CIP1 promoter independent of p53 by the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) through the Sp1 sites. Oncogene 19(50), 5712-5719 (2000).
78. Verbrugge I, Johnstone RW, Bots M. Promises and challenges of anticancer drugs that target the epigenome. Epigenomics 3(5), 547-565 (2011).
79. Robert C, Rassool FV. HDAC inhibitors: roles of DNA damage and repair. Adv. Cancer Res. 116, 87-129 (2012).
80. Sharma SV, Lee DY, Li B et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 141(1), 69-80 (2010).
81. Gore SD, Weng LJ, Figg WD et al. Impact of prolonged infusions of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia. Clin. Cancer Res. 8(4), 963-970 (2002).
82. Olsen EA, Kim YH, Kuzel TM et al. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J. Clin. Oncol. 25(21), 3109-3115 (2007).
83. Piekarz Rl, Frye R, Turner M et al. Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J. Clin. Oncol. 27(32), 5410-5417 (2009).
84. Thaler F. Current trends in the development of histone deacetylase inhibitors: a review of recent patent applications. Pharm. Pat. Anal. 1(1), 75-90 (2012).
85. Marks PA. Discovery and development of SAHA as an anticancer agent. Oncogene 26(9), 1351-1356 (2007).
86. Vansteenkiste J, Van Cutsem E, Dumez H et al. Early Phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer. Invest. New Drugs 26(5), 483-488 (2008).
87. Luu TH, Morgan RJ, Leong L et al. A Phase II trial of vorinostat (suberoylanilide hydroxamic acid) in metastatic breast cancer: a California Cancer Consortium study. Clin. Cancer Res. 14(21), 7138-7142 (2008).
88. Woyach JA, Kloos RT, Ringel MD et al. Lack of therapeutic effect of the histone deacetylase inhibitor vorinostat in patients with metastatic radioiodine-refractory thyroid carcinoma. J. Clin. Endocrinol. Metab. 94(1), 164-170 (2009).
89. Modesitt SC, Sill M, Hoffman JS, Bender DP. A Phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol. Oncol. 109(2), 182-186 (2008).
90. Blumenschein GR Jr, Kies MS, Papadimitrakopoulou VA et al. Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer. Invest. New Drugs 26(1), 81-87 (2008).
91. Traynor AM, Dubey S, Eickhoff JC et al. Vorinostat (NSC# 701852) in patients with relapsed non-small cell lung cancer: a Wisconsin Oncology Network Phase II study. J. Thorac. Oncol. 4(4), 522-526 (2009).
92. Galanis E, Jaeckle KA, Maurer MJ et al. Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study. J. Clin. Oncol. 27(12), 2052-2058 (2009).
93. Schrump DS, Fischette MR, Nguyen DM et al. Clinical and molecular responses in lung cancer patients receiving Romidepsin. Clin. Cancer Res. 14(1), 188-198 (2008).
94. Otterson GA, Hodgson L, Pang H, Vokes EE. Phase II study of the histone deacetylase inhibitor Romidepsin in relapsed small cell lung cancer (Cancer and Leukemia Group B 30304). J. Thorac. Oncol. 5(10), 1644-1648 (2010).
95. Iwamoto FM, Lamborn KR, Kuhn JG et al. A Phase I/ II trial of the histone deacetylase inhibitor romidepsin for adults with recurrent malignant glioma: North American Brain Tumor Consortium Study 03-03. Neuro. Oncol. 13(5), 509-516 (2011).
96. Sherman EJ, Su YB, Lyall A et al. Evaluation of romidepsin for clinical activity and radioactive iodine reuptake in radioactive iodine-refractory thyroid carcinoma. Thyroid 23(5), 593-599 (2013).
97. Whitehead RP, Rankin C, Hoff PM et al. Phase II trial of romidepsin (NSC-630176) in previously treated colorectal cancer patients with advanced disease: a Southwest Oncology Group study (S0336). Invest. New Drugs 27(5), 469-475 (2009).
98. Haigentz M, Jr., Kim M, Sarta C et al. Phase II trial of the histone deacetylase inhibitor romidepsin in patients with recurrent/metastatic head and neck cancer. Oral Oncol. 48(12), 1281-1288 (2012).
99. Molife LR, Attard G, Fong PC et al. Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC). Ann. Oncol. 21(1), 109-113 (2010).
100. Yeo W, Chung HC, Chan SL et al. Epigenetic therapy using belinostat for patients with unresectable hepatocellular carcinoma: a multicenter Phase I/II study with biomarker and pharmacokinetic analysis of tumors from patients in the Mayo Phase II Consortium and the Cancer Therapeutics Research Group. J. Clin. Oncol. 30(27), 3361-3367 (2012).
101. Dizon DS, Blessing JA, Penson RT et al. A Phase II evaluation of belinostat and carboplatin in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol. Oncol. 125(2), 367-371 (2012).
102. Tarhini AA, Zahoor H, Mclaughlin B et al. Phase I trial of carboplatin and etoposide in combination with panobinostat in patients with lung cancer. Anticancer Re.s 33(10), 4475-4481 (2013).
103. Cassier PA, Lefranc A, Amela EY et al. A Phase II trial of panobinostat in patients with advanced pretreated soft tissue sarcoma. A study from the French Sarcoma Group. Br. J. Cancer 109(4), 909-914 (2013).
104. Witta SE, Jotte RM, Konduri K et al. Randomized Phase II trial of erlotinib with and without entinostat in patients with advanced non-small-cell lung cancer who progressed on prior chemotherapy. J. Clin. Oncol. 30(18), 2248-2255 (2012).
105. Yardley DA, Ismail-Khan RR, Melichar B et al. Randomized Phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal aromatase inhibitor. J. Clin. Oncol. 31(17), 2128-2135 (2013).
106. Dong M, Ning ZQ, Xing PY et al. Phase I study of chidamide (CS055/HBI-8000), a new histone deacetylase inhibitor, in patients with advanced solid tumors and lymphomas. Cancer Chemother. Pharmacol. 69(6), 1413-1422 (2012).
107. Zorzi AP, Bernstein M, Samson Y et al. A Phase I study of histone deacetylase inhibitor, pracinostat (SB939), in pediatric patients with refractory solid tumors: IND203 a trial of the NCIC IND program/C17 pediatric Phase I consortium. Pediatr. Blood Cancer 60(11), 1868-1874 (2013).
108. De Bono JS, Kristeleit R, Tolcher A et al. Phase I pharmacokinetic and pharmacodynamic study of LAQ824, a hydroxamate histone deacetylase inhibitor with a heat shock protein-90 inhibitory profile, in patients with advanced solid tumors. Clin. Cancer Res. 14(20), 6663-6673 (2008).
109. Yuan Y, Tang AJ, Castoreno AB et al. Gossypol and an HMT G9a inhibitor act in synergy to induce cell death in pancreatic cancer cells. Cell Death Dis. 4, e690 (2013).
110. Bao B, Ali S, Banerjee S et al. Curcumin analogue CDF inhibits pancreatic tumor growth by switching on suppressor microRNAs and attenuating EZH2 expression. Cancer Res. 72(1), 335-345 (2012).
111. Bar-Sela G, Epelbaum R, Schaffer M. Curcumin as an anticancer agent: review of the gap between basic and clinical applications. Curr. Med. Chem. 17(3), 190-197 (2010).
112. Parasramka MA, Ali S, Banerjee S, Deryavoush T, Sarkar FH, Gupta S. Garcinol sensitizes human pancreatic adenocarcinoma cells to gemcitabine in association with microRNA signatures. Mol Nutr. Food Res. 57(2), 235-248 (2013).
113. Zhao Y, Yang CY, Wang S. The making of I-BET762, a BET bromodomain inhibitor now in clinical development. J. Med. Chem. 56(19), 7498-7500 (2013).
114. Wang M, Chen C, Xu J et al. Effect of bromdomain protein 4 inhibitor GSK525762A on the proliferation and apoptosis of B-cell acute lymphoblastic leukemia cells and its mechanism. Zhonghua Xue Ye Xue Za Zhi 35(6), 528-532 (2014).
115. Cameron EE, Bachman KE, Myohanen S, Herman JG, Baylin SB. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat. Genet. 21(1), 103-107 (1999).
116. Belinsky SA, Klinge DM, Stidley CA et al. Inhibition of DNA methylation and histone deacetylation prevents murine lung cancer. Cancer Res. 63(21), 7089-7093 (2003).
117. Belinsky SA, Grimes MJ, Picchi MA et al. Combination therapy with vidaza and entinostat suppresses tumor growth and reprograms the epigenome in an orthotopic lung cancer model. Cancer Res. 71(2), 454-462 (2011).
118. Stathis A, Hotte SJ, Chen EX et al. Phase I study of decitabine in combination with vorinostat in patients with advanced solid tumors and non-Hodgkins lymphomas. Clin. Cancer Res. 17(6), 1582-1590 (2011).
119. Nilofer AA, Michelle M, Douglas A et al. A phase 2 study of azacitidine and entinostat in patients with metastatic colorectal cancer. ASCO, (2014).
120. Roisin CR, Cynthia Z, Zhe Z et al. A Phase 2 Study investigating the safety, efficacy and surrogate biomarkers of response of 5-Azacitidine and Entinostat in patients with advanced breast cancer. 2014 ASCO Annual Meeting. Chicago, IL, USA, 30 May-3 June 2014.
121. Richards EJ, Elgin SC. Epigenetic codes for heterochromatin formation and silencing: rounding up the usual suspects. Cell 108(4), 489-500 (2002).
122. Tamaru H, Selker EU. A histone H3 methyltransferase controls DNA methylation in Neurospora crassa. Nature 414(6861), 277-283 (2001).
123. Vaissiere T, Sawan C, Herceg Z. Epigenetic interplay between histone modifications and DNA methylation in gene silencing. Mutat. Res. 659(1-2), 40-48 (2008).
124. Keen JC, Yan L, Mack KM et al. A novel histone deacetylase inhibitor, scriptaid, enhances expression of functional estrogen receptor alpha (ER) in ER negative human breast cancer cells in combination with 5-aza 2-deoxycytidine. Breast Cancer Res. Treat. 81(3), 177-186 (2003).
125. Sharma D, Saxena NK, Davidson NE, Vertino PM. Restoration of tamoxifen sensitivity in estrogen receptornegative breast cancer cells: tamoxifen-bound reactivated ER recruits distinctive corepressor complexes. Cancer Res. 66(12), 6370-6378 (2006).
126. Fan J, Yin WJ, Lu JS et al. ER alpha negative breast cancer cells restore response to endocrine therapy by combination treatment with both HDAC inhibitor and DNMT inhibitor. J. Cancer Res. Clin. Oncol. 134(8), 883-890 (2008).
127. Yang X, Phillips Dl, Ferguson AT, Nelson WG, Herman JG, Davidson NE. Synergistic activation of functional estrogen receptor (ER)-alpha by DNA methyltransferase and histone deacetylase inhibition in human ER-alpha-negative breast cancer cells. Cancer Res. 61(19), 7025-7029 (2001).
128. Munster PN, Thurn KT, Thomas S et al. A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapyresistant breast cancer. Br. J. Cancer 104(12), 1828-1835 (2011).
129. ClinicalTrials.gov. NCT01234532 (2010).
130. ClinicalTrials.gov. NCT02115282 (2014).
131. Easwaran H, Tsai HC, Baylin SB. Cancer epigenetics: tumor heterogeneity, plasticity of stem-like states, and drug resistance. Mol. Cell 54(5), 716-727 (2014).
132. Wang Y, Cardenas H, Fang F et al. Epigenetic targeting of ovarian cancer stem cells. Cancer Res. 74(17), 4922-4936 (2014).
133. Humeniuk R, Menon LG, Mishra PJ et al. Decreased levels of UMP kinase as a mechanism of fluoropyrimidine resistance. Mol. Cancer Ther. 8(5), 1037-1044 (2009).
134. Meng F, Sun G, Zhong M, Yu Y, Brewer MA. Anticancer efficacy of cisplatin and trichostatin A or 5-aza-2- deoxycytidine on ovarian cancer. Br. J. Cancer 108(3), 579-586 (2013).
135. Fu S, Hu W, Iyer R et al. Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer. Cancer 117(8), 1661-1669 (2011).
136. Appleton K, Mackay HJ, Judson I et al. Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors. J. Clin. Oncol. 25(29), 4603-4609 (2007).
137. Falchook GS, Fu S, Naing A et al. Methylation and histone deacetylase inhibition in combination with platinum treatment in patients with advanced malignancies. Invest. New Drugs 31(5), 1192-1200 (2013).
138. Matei D, Fang F, Shen C et al. Epigenetic resensitization to platinum in ovarian cancer. Cancer Res. 72(9), 2197-2205 (2012).
139. Glasspool RM, Brown R, Gore ME et al. A randomised, Phase II trial of the DNA-hypomethylating agent 5-aza-2- deoxycytidine (decitabine) in combination with carboplatin vs carboplatin alone in patients with recurrent, partially platinum-sensitive ovarian cancer. Br. J. Cancer 110(8), 1923-1929 (2014).
140. Ramalingam SS, Maitland Ml, Frankel P et al. Carboplatin and Paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancer. J. Clin. Oncol. 28(1), 56-62 (2010).
141. Ramaswamy B, Fiskus W, Cohen B et al. Phase I-II study of vorinostat plus paclitaxel and bevacizumab in metastatic breast cancer: evidence for vorinostat-induced tubulin acetylation and Hsp90 inhibition in vivo. Breast Cancer Res. Treat. 132(3), 1063-1072 (2012).
142. Edwards A, Li J, Atadja P, Bhalla K, Haura EB. Effect of the histone deacetylase inhibitor LBH589 against epidermal growth factor receptor-dependent human lung cancer cells. Mol. Cancer Ther. 6(9), 2515-2524 (2007).
143. Reguart N, Rosell R, Cardenal F et al. Phase I/II trial of vorinostat (SAHA) and erlotinib for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations after erlotinib progression. Lung Cancer 84(2), 161-167 (2014).
144. Hoang T, Campbell TC, Zhang C et al. Vorinostat and bortezomib as third-line therapy in patients with advanced non-small cell lung cancer: a Wisconsin Oncology Network Phase II study. Invest. New Drugs 32(1), 195-199 (2014).
145. Garrido-Laguna I, Mcgregor KA, Wade M et al. A phase I/ II study of decitabine in combination with panitumumab in patients with wild-type (wt) KRAS metastatic colorectal cancer. Invest. New Drugs 31(5), 1257-1264 (2013).
146. Chaudhry MA, Omaruddin RA. Differential DNA methylation alterations in radiation-sensitive and -resistant cells. DNA Cell. Biol. 31(6), 908-916 (2012).
147. Li Y, Geng P, Jiang W et al. Enhancement of radiosensitivity by 5-Aza-CdR through activation of G2/M checkpoint response and apoptosis in osteosarcoma cells. Tumour Biol. 35(5), 3841-3849 (2014).
148. Ren J, Chu Y, Ma H et al. Epigenetic interventions increase the radiation sensitivity of cancer cells. Curr. Pharm. Des. 20(11), 1857-1865 (2014).
149. Zhang Y, Jung M, Dritschilo A. Enhancement of radiation sensitivity of human squamous carcinoma cells by histone deacetylase inhibitors. Radiat. Res. 161(6), 667-674 (2004).
150. Cuneo KC, Fu A, Osusky K, Huamani J, Hallahan DE, Geng L. Histone deacetylase inhibitor NVP-LAQ824 sensitizes human nonsmall cell lung cancer to the cytotoxic effects of ionizing radiation. Anticancer. Drugs 18(7), 793-800 (2007).
151. Knipstein JA, Birks DK, Donson AM, Alimova I, Foreman NK, Vibhakar R. Histone deacetylase inhibition decreases proliferation and potentiates the effect of ionizing radiation in atypical teratoid/rhabdoid tumor cells. Neuro. Oncol. 14(2), 175-183 (2012).
152. Shi W, Lawrence YR, Choy H et al. Vorinostat as a radiosensitizer for brain metastasis: a Phase I clinical trial. J. Neurooncol. 118(2), 313-319 (2014).
153. Shabason JE, Tofilon PJ, Camphausen K. Grand rounds at the National Institutes of Health: HDAC inhibitors as radiation modifiers, from bench to clinic. J. Cell. Mol. Med. 15(12), 2735-2744 (2011).
154. Sigalotti L, Coral S, Nardi G et al. Promoter methylation controls the expression of MAGE2, 3 and 4 genes in human cutaneous melanoma. J. Immunother. 25(1), 16-26 (2002).
155. Sigalotti L, Covre A, Zabierowski S et al. Cancer testis antigens in human melanoma stem cells: expression, distribution, and methylation status. J. Cell. Physiol. 215(2), 287-291 (2008).
156. Weber J, Salgaller M, Samid D et al. Expression of the MAGE-1 tumor antigen is up-regulated by the demethylating agent 5-aza-2-deoxycytidine. Cancer Res. 54(7), 1766-1771 (1994).
157. Wischnewski F, Pantel K, Schwarzenbach H. Promoter demethylation and histone acetylation mediate gene expression of MAGE-A1, -A2, -A3, and -A12 in human cancer cells. Mol. Cancer Res. 4(5), 339-349 (2006).
158. Luo W, Wang X, Kageshita T, Wakasugi S, Karpf Ar, Ferrone S. Regulation of high molecular weight-melanoma associated antigen (HMW-MAA) gene expression by promoter DNA methylation in human melanoma cells. Oncogene 25(20), 2873-2884 (2006).
159. Qifeng S, Bo C, Xingtao J, Chuanliang P, Xiaogang Z. Methylation of the promoter of human leukocyte antigen class I in human esophageal squamous cell carcinoma and its histopathological characteristics. J. Thorac. Cardiovasc. Surg. 141(3), 808-814 (2011).
160. Ye Q, Shen Y, Wang X et al. Hypermethylation of HLA class I gene is associated with HLA class I down-regulation in human gastric cancer. Tissue Antigens 75(1), 30-39 (2010).
161. Kitamura H, Torigoe T, Asanuma H, Honma I, Sato N, Tsukamoto T. Down-regulation of HLA class I antigens in prostate cancer tissues and up-regulation by histone deacetylase inhibition. J. Urol. 178(2), 692-696 (2007).
162. Magner WJ, Kazim Al, Stewart C et al. Activation of MHC class I, II, and CD40 gene expression by histone deacetylase inhibitors. J. Immunol. 165(12), 7017-7024 (2000).
163. Mora-Garcia Mde L, Duenas-Gonzalez A, Hernandez- Montes J et al. Up-regulation of HLA class-I antigen expression and antigen-specific CTL response in cervical cancer cells by the demethylating agent hydralazine and the histone deacetylase inhibitor valproic acid. J. Transl. Med. 4, 55 (2006).
164. Skov S, Pedersen MT, Andresen L, Straten PT, Woetmann A, Odum N. Cancer cells become susceptible to natural killer cell killing after exposure to histone deacetylase inhibitors due to glycogen synthase kinase-3-dependent expression of MHC class I-related chain A and B. Cancer Res. 65(23), 11136-11145 (2005).
165. Christiansen AJ, West A, Banks KM et al. Eradication of solid tumors using histone deacetylase inhibitors combined with immune-stimulating antibodies. Proc. Natl Acad. Sci. USA 108(10), 4141-4146 (2011).
166. Luchenko Vl, Salcido CD, Zhang Y et al. Scheduledependent synergy of histone deacetylase inhibitors with DNA damaging agents in small cell lung cancer. Cell Cycle 10(18), 3119-3128 (2011).
167. Seymour L, Ivy SP, Sargent D et al. The design of Phase II clinical trials testing cancer therapeutics: consensus recommendations from the clinical trial design task force of the national cancer institute investigational drug steering committee. Clin. Cancer Res. 16(6), 1764-1769 (2010).
168. Dhani N, Tu D, Sargent DJ, Seymour L, Moore MJ. Alternate endpoints for screening phase II studies. Clin. Cancer Res. 15(6), 1873-1882 (2009).
169. Shankar LK, Van Den Abbeele A, Yap J, Benjamin R, Scheutze S, Fitzgerald TJ. Considerations for the use of imaging tools for Phase II treatment trials in oncology. Clin. Cancer Res. 15(6), 1891-1897 (2009).